KR102294577B1 - 고체 경구 제형 - Google Patents

고체 경구 제형 Download PDF

Info

Publication number
KR102294577B1
KR102294577B1 KR1020177022584A KR20177022584A KR102294577B1 KR 102294577 B1 KR102294577 B1 KR 102294577B1 KR 1020177022584 A KR1020177022584 A KR 1020177022584A KR 20177022584 A KR20177022584 A KR 20177022584A KR 102294577 B1 KR102294577 B1 KR 102294577B1
Authority
KR
South Korea
Prior art keywords
delete delete
acid
dosage form
solid oral
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177022584A
Other languages
English (en)
Korean (ko)
Other versions
KR20170103942A (ko
Inventor
존 브레토스
토마스 다그스
폴 실즈
레이먼도 클라우디오
Original Assignee
엔터리스 바이오파마, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔터리스 바이오파마, 인크. filed Critical 엔터리스 바이오파마, 인크.
Publication of KR20170103942A publication Critical patent/KR20170103942A/ko
Application granted granted Critical
Publication of KR102294577B1 publication Critical patent/KR102294577B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177022584A 2015-01-12 2016-01-12 고체 경구 제형 Active KR102294577B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562102263P 2015-01-12 2015-01-12
US62/102,263 2015-01-12
US14/993,294 2016-01-12
US14/993,294 US9833411B2 (en) 2015-01-12 2016-01-12 Solid oral dosage forms
PCT/US2016/012970 WO2016115082A1 (en) 2015-01-12 2016-01-12 Solid oral dosage forms

Publications (2)

Publication Number Publication Date
KR20170103942A KR20170103942A (ko) 2017-09-13
KR102294577B1 true KR102294577B1 (ko) 2021-08-26

Family

ID=56366726

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177022584A Active KR102294577B1 (ko) 2015-01-12 2016-01-12 고체 경구 제형

Country Status (10)

Country Link
US (2) US9833411B2 (https=)
EP (1) EP3244878B1 (https=)
JP (1) JP6910950B2 (https=)
KR (1) KR102294577B1 (https=)
CN (1) CN107427469B (https=)
AU (1) AU2016206950B2 (https=)
CA (1) CA2973099C (https=)
DK (1) DK3244878T3 (https=)
ES (1) ES2929218T3 (https=)
WO (1) WO2016115082A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
CN118634202A (zh) * 2016-08-05 2024-09-13 帕克治疗公司 室温稳定的口服降钙素制剂
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
CN108065443B (zh) * 2017-12-30 2020-02-28 厦门金达威维生素有限公司 斥水型双包被微胶囊及其制备方法
EP3610862A1 (en) * 2018-08-14 2020-02-19 Apillet APS Novel oral composition
MX2022001975A (es) * 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN114901262A (zh) * 2019-11-04 2022-08-12 辛克鲁斯制药控股有限公司 X842的口服制剂
EP4096698A1 (en) 2020-01-28 2022-12-07 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
CN112956699A (zh) * 2021-01-27 2021-06-15 上海海洋大学 一种降血糖肽肠溶固体分散体及其制备方法
US20250073309A1 (en) * 2021-04-08 2025-03-06 Enteris Biopharma, Inc. Methods of treatment of pediatric puberty using oral formulations of leuprolide
MX2024005292A (es) 2021-11-05 2024-05-17 Cinclus Pharma Holding Ab Publ Polimorfos de la sal de clorhidrato de glurato de linaprazan.
JP2025519656A (ja) 2022-06-13 2025-06-26 ビー．エー．アイ． ラボラトリーズ， エルエルシー インターロイキン－１３結合環状オリゴペプチドおよびその使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525123A (ja) 2001-03-08 2004-08-19 ユニジーン・ラボラトリーズ・インコーポレーテッド 経口ペプチド医薬投与形および製造方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
FR2628429B1 (fr) 1988-03-08 1990-12-28 Transgene Sa Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20010055648A1 (en) 1999-12-14 2001-12-27 Primera Foods Corporation Apparatus and process for coating particles
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
CA2445860A1 (en) 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US20050123507A1 (en) 2003-06-30 2005-06-09 Mahmoud Ameri Formulations for coated microprojections having controlled solubility
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
EP1758927A4 (en) 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
CN101056650A (zh) 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2006125762A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
BRPI0620430A2 (pt) 2005-12-22 2011-11-08 Wyeth Corp métodos para tratar infecções do trato gastrointestinal com tigeciclina
WO2007075794A2 (en) * 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
JP2009523784A (ja) * 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
EP2086515A2 (en) * 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
MX350380B (es) * 2006-05-09 2017-09-05 SpecGx LLC Formas de dosificacion solida de liberacion modificada en el orden de cero.
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
EP2155167A2 (en) * 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN101380461B (zh) * 2008-09-27 2011-09-07 吴建中 高效的胸腺肽肠溶片和注射用胸腺肽
US20100256060A1 (en) 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
JP2012144436A (ja) * 2009-04-30 2012-08-02 Takeda Chem Ind Ltd 併用剤
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012098187A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
EP2665470A1 (en) 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
CA2839408A1 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9102753B2 (en) 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
IN2015DN03132A (https=) * 2012-09-17 2015-10-02 Tarix Pharmaceuticals Ltd
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP2016524617A (ja) 2013-05-30 2016-08-18 ノヴォ ノルディスク アー／エス 糖尿病の治療のための新規な経口医薬組成物
WO2015162195A1 (en) 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US20180263915A1 (en) 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525123A (ja) 2001-03-08 2004-08-19 ユニジーン・ラボラトリーズ・インコーポレーテッド 経口ペプチド医薬投与形および製造方法

Also Published As

Publication number Publication date
CN107427469B (zh) 2021-01-26
KR20170103942A (ko) 2017-09-13
JP6910950B2 (ja) 2021-07-28
EP3244878B1 (en) 2022-08-10
EP3244878A1 (en) 2017-11-22
CN107427469A (zh) 2017-12-01
CA2973099A1 (en) 2016-07-21
AU2016206950A1 (en) 2017-07-27
US20180049987A1 (en) 2018-02-22
WO2016115082A1 (en) 2016-07-21
ES2929218T3 (es) 2022-11-28
JP2018501292A (ja) 2018-01-18
US20160199303A1 (en) 2016-07-14
DK3244878T3 (da) 2022-10-17
US9833411B2 (en) 2017-12-05
AU2016206950B2 (en) 2021-05-06
CA2973099C (en) 2021-09-14

Similar Documents

Publication Publication Date Title
KR102294577B1 (ko) 고체 경구 제형
DK2152195T3 (en) Peptide drug for oral delivery
US7316819B2 (en) Oral peptide pharmaceutical dosage form and method of production
CN103764159A (zh) 芳香族阳离子肽及其用途
CN105101950B (zh) 口服递送的药物
JP2012111773A (ja) 経口吸収改善用医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170811

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210108

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20210108

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210526

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210823

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210823

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240722

Start annual number: 4

End annual number: 4